Advancements in HR+/HER2-Negative Breast Cancer Management

This webinar focuses on HR+/HER2-negative breast cancer, featuring a distinguished panel of two expert physicians. This insightful event aims to delve into the diverse therapeutic approaches available for this specific subtype of breast cancer. Our esteemed panelists, with their extensive clinical experience and expertise, will discuss the latest advancements in treatment options, providing valuable insights into the evolving landscape of HR+/HER2-negative breast cancer management.

Join us as we explore the detailed aspects of therapeutic strategies, examine the latest research findings, and discuss potential future developments. This webinar offers a comprehensive overview of current treatment modalities, emphasizing their impact on patient outcomes and quality of life. This informative session is designed for healthcare professionals and individuals within the pharmaceutical industry. It offers a valuable opportunity for these professionals to enhance their understanding of HR+/HER2-negative breast cancer and stay updated on the evolving treatment landscape.

Joyce O’Shaughnessy – Baylor-Sammons Cancer Center

Joyce A. O’Shaughnessy, M.D.- Biography

Celebrating Women Endowed Chair in Breast Cancer Research, Baylor University Medical Center, Dallas, Texas

Baylor Charles A. Sammons Cancer Center, Texas Oncology, SCRI, Dallas Texas

Joyce A. O’Shaughnessy, M.D. specializes in medical oncology with board certification in both internal medicine as well as medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Dr. O’Shaughnessy focuses on her practice and clinical research on breast cancer treatment. She is Director of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center and Chair of the Breast Disease Committee for Sarah Cannon Research Institute in Dallas, TX.

Background / Education:

Dr. O’Shaughnessy received her M.D. from Yale University Medical School. Her internship and residency in internal medicine were completed at Massachusetts General Hospital in 1985. She concluded a fellowship in medical oncology at the National Cancer Institute in 1987 and was a Senior Investigator there until 1995.

Memberships:

Member: American Association for Cancer Research; American Society of Clinical Oncology; Founder: The School of Breast Oncology

Honors/Awards:

Giants of Cancer Care: Community Outreach/Education Award; Baylor University Medical Center: Staff Chief’s award; Holy Cross College: Santae Crucis Award (Distinguished Alumni Award): Public Health Service Special Service: Development of the Consensus Statement on

Cancer Drug Approval Endpoints Award; Yale Medical School: Francis Parker Award (Faculty Choice for Most Promising Clinician)

Research Interests: Genotype-Phenotype correlations for high risk breast cancers and immunotherapy for triple negative breast cancer.

Adrienne Waks – Dana-Farber Cancer Institute

Adrienne G. Waks, MD, is an Assistant Professor of Medicine at Harvard Medical School and the Associate Director of Breast Oncology Clinical Research at Dana-Farber Cancer Institute. She specializes in breast cancer, immuno-oncology, and novel therapies for breast cancer. Dr. Waks received her medical degree from Harvard Medical School, completed her residency at Brigham and Women's Hospital, including a year as Chief Resident, and finalized her fellowship in medical oncology at Dana-Farber/Partners CancerCare. She is board-certified in internal medicine and medical oncology.